The overall goal of this program is to emphasize scientific paradigms focused on treatment of local / regional disease, with the ultimate objective of achieving long term control of such tumors, while maintaining normal tissue integrity. The paradigm is being approached two ways: 1) Therapeutic approaches to increase tumor response or reduce normal tissue damage, and 2) Development of diagnostic methods to predict outcome or guide therapeutic decisions before or during treatment. The fact that radiation therapy is used as part of therapy for nearly all forms of cancer means that the clinical collaborations are varied and multidisciplinary. Members cross many disciplines, including molecular biology and signal transduction, transgenic model development, physiology, angiogenesis, hyperthermia, engineering, drug carrier development, imaging, radiation biology and clinical trial development and conduct. This program is centered in a clinical department, which helps to focus efforts toward translational studies. The program has incorporated MR and CT/PET imaging capabilities into research activities with the acquisition of this hardware for research purposes. Several protocols now include opportunities for direct acquisition of tissues and / or plasma samples that can be used for correlative science investigations. Significant improvement has been made in the basic science component of the program, with successful recruitment of clinical faculty with interests in transgenic models of human cancer and in translational studies involving breast cancer radiotherapy. The program sponsors several venues for interaction, offered on a bi-weekly to yearly basis to facilitate collaborations within and with other programs. Since the last competing renewal, members of this program have published 424 peer reviewed papers;over 90% of which have been directly related to cancer. Nearly 50% of the publications have involved inter- or intra- programmatic collaborations. The patient census has grown by 35%, from 978 treatment starts in 2004 to well over 1300 in 2007. The percentage of patients enrolled on protocols has averaged just over 6%. Accrual of minorities and women has averaged 18% and 57%, respectively. Clinical trial and grants management infrastructure has been substantially improved, which is paying dividends with respect to easing initiation of new investigator initiated trials. The Program includes 24 members from 5 basic and clinical departments. Total funding for program members is $12,819,957, of Which $8,288,024 is from peer-reviewed sources. A cancer focus is illustrated by $4,758,760 or 57.4% of funding from the NCI, the American Cancer Society or the Department of Defense.

Public Health Relevance

Approximately 50% of all cancer patients are treated with radiotherapy, and of those, a significant percentage are treated with curative intent. Given the widespread use of this modality, it is imperative that means be established to increase the likelihood that local tumor control can be achieved, while preserving the integrity of normal tissues. This common paradigm fits this program well, but it is now being addressed with modern radiotherapy practices in the context of cutting-edge imaging and translational sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-39
Application #
8424157
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$33,150
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications